Midatech Pharma Share Discussion Threads

[deltrotter] 26/4/2016 15:51

Tx ProactiveST

[proactivest] 26/4/2016 15:30

Video interview with Jim Phillips



Jim Phillips, chief executive at Midatech Pharma (LON:MTPH) tells Proactive Investors about the good results from a pre-clinical study of Q-Octreotide, its treatment for the side effects of carcinoid tumours.

The company has "a really exciting product that is the next generation of that type of therapy," says Phillips.

The company is investing to scale up production at its Bilbao site in Spain so it can start to commercially produce the treatment. It is also preparing for the clinical trial that will start at the end of the year/beginning of next year.

[thomasthetank1] 26/4/2016 12:47

Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63
"More good news this morning. Positive pharmacokinetic data from Midatech’s Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome demonstrate a favourable profile against the reference and market leader Sandostatin LAR Depot (Novartis). This paves the way towards IND submission and bio-equivalence in human studies expected in late 2016 and today’s news adds further weight and momentum to the company’s recent news flow. With significant headroom on the current share price ..."

[cliveas] 26/4/2016 07:15

RNS ;

~ Release profile of Midatech's Q-Octreotide compared favourably with the reference product and current market leader ~



Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology and other therapeutic areas, today announces positive pharmacokinetic data with its Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome. The pilot preclinical study confirmed the systemic release profile of Midatech's Q-Octreotide compared favourably with the reference Octreotide product and current market leader, Sandostatin® LAR Depot (Novartis).



Commenting on the announcement, Dr. Jim Phillips, Chief Executive Officer of Midatech Pharma, said: "Q-Octreotide is one of the most advanced of our in-house cancer treatments. Whilst preparing the programme for clinical development, the existing use of Octreotide gives us confidence that this programme can be progressed quickly. We look forward to continuing to develop our internal pipeline of cancer therapies with Q-Octreotide near the front. Furthermore we are delighted now to be progressing with the investment in commercial scale up of production in our Bilbao facility in Spain, which will enable Q-Octreotide and other projects to be manufactured in-house, enabling us to capture more of the integrated value chain."



MTD201, a sustained release version of Octreotide, is used to treat the incapacitating symptoms of metastatic carcinoid tumours, where it suppresses or inhibits the severe diarrhoea and flushing episodes associated with the disease, and to normalise the over-production of growth hormone in people suffering acromegaly who have had inadequate response to other therapies. Midatech plans on submitting its investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) and begin bio-equivalence studies in late 2016.



Q-Octreotide is a wholly-owned asset of Midatech Pharma and will continue to be developed in-house. Subject to regulatory approval, Midatech expects to commercialize Q-Octreotide in the United States through its Midatech Pharma U.S. subsidiary.

[mfhmfh] 25/4/2016 15:02

They hinted the insulin trial was going well but we'll have to wait and see.

Regarding the patient in Bristol, I seem to remember from the presentation she was a 5 yr old girl with Diffuse intrinsic pontine glioma (DIPG).

This from wikipedia about DIPG (very aggressive cancer):

DIPG has a 0% survival rate. The median overall survival of children diagnosed with DIPG is approximately 9 months. The 1 and 2 year survival rates are approximately 30% and less than 10%, respectively. These statistics make it one of the most devastating pediatric malignancies.

Hopefully our treatment will help prolong but unlikely to cure. They did mention that other countries had contacted them about trying the treatment for cases in children they had.

[deltrotter] 25/4/2016 12:08

I think they are now say H1 mfh, so could be up to two months longer.

Should also hear some news about the Bristol patient with brain cancer (fingers crossed for that poor soul that it has worked).

[mfhmfh] 25/4/2016 11:27

476p will do very nicely. I'm waiting for results of a trial for buccal (mouth) insulin for Diabetes which were scheduled to be delivered in April.

[fillipe] 25/4/2016 10:46

185p paid....a nice recovery from the recent brief downdip.

The most recent tp I see is that from PanGord 13-4-2016, of 476p.

That'll do nicely...

f

[martinwj] 25/4/2016 09:48

Spread tightened to 3p and up 5% so far. Looks like they have an order to fill.

[deltrotter] 22/4/2016 11:26

Interview with the gaffer:

[thomasthetank1] 21/4/2016 16:54

Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63
"Midatech Pharma has delivered on the first of its near-term updates with the announcement of positive data from its OpsiSporin (MTD202) programme, a sustained release treatment with Q-Cyclosporin (3-monthly injectable formulation) for the treatment of non-infective uveitis (currently a circa $1.3bn market). The positive preclinical work now paves the way towards a formal IND (Investigational New Drug) enabling and toxicology programme which is now being finalised prior to an expected IND submission in 2H17, and we consider this to be a programme with strong partnering potential. Ongoing news flow following last week’s results announcement demonstrates strong momentum..."

[18bt] 21/4/2016 08:50

Useful results for uveitis drug. Need more positive newsflow.

[hutch_pod] 14/4/2016 15:28

I always thought the Insulin Phase IIa JV was a key driver of value (roughly half the NPV that Edison calculate), and yet it seems downplayed in these results as non-core ( as compared to oncology ).

[thomasthetank1] 13/4/2016 12:33

Read Panmure's note on Midatech Pharma (MTPH), out this morning, by visiting www.research-tree.com …
“Today’s FY15 results see revenues of £1.38m ahead of our expectations (PGe £1.30m, 2014: £0.16m) and, adjusting for one-off listing/acquisition items, the strong performance is also reflected at the bottom-line, with adjusted pre-tax loss of £9.9m vs PGe £10.6m loss. Delivery of this kind, during a period of high activity, reflects well on management capabilities and bandwidth. The parallel strands of commercial and pipeline development bode well for the long-term risk and growth profile of the business and we note strong revenues from marketed products in the first three months of 2016 with trading ‘slightly ahead of market expectations’. We retain our earnings forecasts unchanged for now but will look to future updates with respect to potential headroom on our forecasts. In the meantime, our view remains that there is significant headroom on the current share price…”

[18bt] 13/4/2016 09:32

Not much comment on IIa insulin other than it completed. OVerall a lot if bullish comments, but difficult to analyse. Happy to rely for the moment on a proven management team.

[knights] 12/4/2016 11:32

apart from the indicated revenue increase. what else is there to look out for in tomorrow results? I have noted down that the Phase IIa insulin study results should be out in time for these results. anything else?

[mfhmfh] 12/4/2016 11:08

Rising into results tomorrow.

[edrifter] 11/4/2016 07:27

RNS advertising the launch of Zuplenz in the US, 2 days ahead of the figures. Interesting move.

[edrifter] 07/4/2016 05:25

Recovered to the post merger level - about 170. It has gone a bit higher in the US (4.80 as opposed to the 4.55 flatline) where I have my meagre stake. I'd happily pick up a few more, but cashflow is limited.

[mfhmfh] 04/4/2016 17:03

hopefully a recovery as results approach on 13th this month

[edrifter] 23/3/2016 01:11

Been watching this since it settled down at 170. Decided the drop to 150 was a tree-shake - no reason to spike down like that on no news - so dipped a toe in via the US ADR issue. Will increase the holding as time opportunity permits. A lot to like here, but it may be a long wait.